P2RY12 and atrial fibrillation: Combination of rivaroxaban 15 mg per day and P2Y12 inhibitor showed a statistically lower risk of MACCEs compared with DAPT and TT regimens for AF patients undergoing PCI (0.64 [0.38, 0.95] and 0.68 [0.43, 0.98], respectively) and owned the first place of efficacy possibility among 5 therapies (Fig 3).